VEGF Trap shows activity in patients with advanced ovarian cancer

Chicago, June 2, 2007 -- Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which are being presented today at the American Society of Clinical Oncologys annual meeting, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.

To date, the trial has enrolled 162 patients with advanced ovarian cancer at 44 centers in twelve countries in Europe, Canada, and the United States. Favorable results were reported for 85 percent of participants after one month: 8 percent showed tumor shrinkage and 77 percent had stable disease. After fourteen weeks, 41 percent of patients continued to have stable disease.

The interim analysis of the Phase II data was very promising, said Dr. William P. Tew, an oncologist at Memorial Sloan-Kettering Cancer Center and the studys lead author. As a result, we are continuing to recruit patients to complete the study.

In this trial, VEGF Trap is administered intravenously as a single agent in one of two dose levels. It works by blocking the development of new blood vessels to the tumor (angiogenesis) which stops tumor growth and the spread of cancer to other parts of the body (metastasis). It can also result in tumor shrinkage. VEGF Trap is generally well-tolerated although both mild and severe side effects were reported. These included but were not limited to headache, fatigue, nausea, mild and severe hypertension, hoarseness, mild and severe protein in the urine, renal dysfunction, and a low incidence of bowel perforation (one percent).

Ovarian cancer may be unusual among solid tumors because vascular-targeting agents like VEGF Trap appear to have significant single-agent activity in advanced ovaria

Contact: Joanne Nicholas
Memorial Sloan-Kettering Cancer Center

Page: 1 2

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:

(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced the 10th Anniversary of Blood Cancer Awareness Month (BCAM) ...
(Date:8/31/2020)... ... 31, 2020 , ... Colorado State University Global (CSU Global) ... online education – is proud to announce its new master’s degree in ... kind in the nation, the 60-credit hour program is designed to provide students ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... working, both directly with persons with autism and other developmental disabilities, as well ... early intervention, parent education, adolescents with autism, school consultation, and staff development. She ...
(Date:8/28/2020)... FOOTHILL RANCH, Calif. (PRWEB) , ... August 28, ... ... NCPCV cover a one-year subscription to a customized Lighthouse Health & Wellness ... in generous support of this project. Motorola Solutions Foundation awards grants each year ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... has joined the Walk-in Dermatology team in its Greenvale, New York location. ... Nail and Skin Care Institute. She is certified in chemical peels, microdermabrasion, Hydrafacial ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... RESTON, Va. (PRWEB) , ... ... ... Alliance (CEA) Holdings company today announced that it has entered into definitive ... healthcare professionals CME/CE, primarily focused on pharmacists and pharmacy technicians. , ...
(Date:8/26/2020)... ... 2020 , ... Crossroads Hospice & Palliative Care Chief Compliance ... her name. , That’s thanks to her completion of two additional certifications this ... Officer (CPCO.) , The CHC is designed to mitigate compliance-related risks. Being ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... devoted to funding innovative lymphoma research and serving the lymphoma community through education ... a special virtual LRF Gala and Charity Auction on Wednesday, Sept. 30 ...
Breaking Medicine Technology:
Cached News: